The rapid growth of artificial intelligence (AI) in healthcare has created opportunities for improving clinical decision-making through smart therapeutic systems. Understanding factors influencing willingness to adopt these technologies is essential for successful implementation. This study examines determinants of behavioral intention to adopt AI-enabled smart therapeutics, defined as AI-driven clinical decision and medication support systems assisting pharmacists in optimizing therapeutic plans, dosing, safety monitoring, and treatment personalization. The sample comprised 407 pharmacy students, faculty members, and practitioners from Jordan, Saudi Arabia, UAE, and Qatar. Eleven hypotheses were tested using structural equation modeling. Results show that attitudes and perceptions, concerns about AI, enterprise support, and trust in AI significantly predict behavioral intention, with enterprise support as the strongest driver. Self-knowledge and perceived barriers did not significantly influence intention. Moderation analysis indicates trust in AI reduces negative impact of perceived barriers and strengthens positive effect of enterprise support. These results underscore the importance of institutional preparedness, trust in AI, and perceptions of enhanced performance in influencing adoption intentions. The study adds to existing research on AI acceptance and offers actionable guidance for organizations implementing AI-enabled smart therapeutics in healthcare settings.